Q3 Earnings Preview For Sarepta Therapeutics

Sarepta Therapeutics, Inc. SRPT announces its next round of earnings this Wednesday, Oct. 24. Here's Benzinga's advanced look at Sarepta's Q3 earnings report.

Earnings and Revenue

Sarepta's per-share loss will be near 82 cents on sales of $79.21 million, according to Wall Street analysts.

Sarepta reported a loss of 20 cents when it published results during the same quarter last year. Sales in that period totaled $45.95 million. If the company were to report inline earnings when it publishes results Wednesday, earnings would be up 310 percent. Revenue would be up 72.37 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q2 2018 Q1 2018 Q4 2017 Q3 2017
EPS Estimate -0.84 -0.32 -0.32 -0.86
EPS Actual -0.43 -0.28 -0.28 -0.2

Stock Performance

Over the last 52-week period, shares are up 158.61 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts generally rate Sarepta stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsEarnings Previews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...